EG 427French targeted DNA gene therapy specialist EG427 has closed a €27m Series B financing co-led by VC investor Andera Partners and BPI France to initiate Phase I testing of a Herpes Simplex Virus 1 (nrHSV-1) vector that specifically targets type C neurons to suppress dysfunctions of the bladder in people with spinal injury.
ADVERTISEMENT